<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465944</url>
  </required_header>
  <id_info>
    <org_study_id>FFP104-002</org_study_id>
    <secondary_id>2015-001678-17</secondary_id>
    <nct_id>NCT02465944</nct_id>
  </id_info>
  <brief_title>A Pilot Study of FFP104 in Subjects With Crohn's Disease</brief_title>
  <official_title>A Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects With Moderate to Severely Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fast Forward Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fast Forward Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the safety, tolerability and efficacy of
      intravenously administered FFP104 or placebo over 15 days (3 total doses) in subjects with
      moderate to severely active Crohn's Disease
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability will be assessed through clinical laboratory tests, vital signs, physical exams, and adverse event assessments</measure>
    <time_frame>Up to 84 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving clinical response (decrease of Crohn's Disease Activity Index (CDAI) score by ≥100 points from baseline)</measure>
    <time_frame>Days 0, 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving clinical remission (attainment of absolute CDAI score of 150 points or less from baseline)</measure>
    <time_frame>Days 0, 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving partial response (decrease of CDAI score by &gt;70 points from baseline)</measure>
    <time_frame>Days 0, 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in CDAI score between FFP104 treated subjects and placebo subjects in each arm of the study</measure>
    <time_frame>Days 0, 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (decrease in CDAI score by &gt;100 points)</measure>
    <time_frame>Days 0, 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to partial response (decrease of CDAI score by &gt;70 points)</measure>
    <time_frame>Days 0, 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Crohn's Disease Endoscopic Index of Severity (CDEIS)</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in gut tissue organisation (histology)</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in faecal calprotectin level</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in C-Reactive Protein (CRP) levels</measure>
    <time_frame>Day 7, 14, 28, 42 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ)</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in health outcome measures</measure>
    <time_frame>Day 42</time_frame>
    <description>Health outcome measures that will be used are Short Form 36 (SF36), the EuroQol EQ-5D-5L and the Work Productivity and Activity Impairment Questionnaire Crohn's Disease (WPAI-CD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate changes from baseline in serum FFP104 levels</measure>
    <time_frame>up to 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate changes in lymphocyte sub-populations in peripheral blood</measure>
    <time_frame>Day 0, 14 and 42</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>FFP104 - 2.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FFP104</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FFP104 - 5.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FFP104</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FFP104</intervention_name>
    <description>Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)</description>
    <arm_group_label>FFP104 - 2.5 mg/kg</arm_group_label>
    <arm_group_label>FFP104 - 5.0 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

        Subjects will be entered into this study only if they meet all of the following criteria:

          -  Willing and able to provide written informed consent.

          -  Willing and able to comply with all study procedures and visits.

          -  Male or female aged between 18 and 75 years, inclusive.

          -  Body Mass Index (BMI) between 18-35 kg/m2.

          -  Clinical diagnosis of Crohn's disease involving the colon and/or ileum for at least 3
             months from Screening confirmed by radiological, endoscopic or histological evidence.

          -  Active Crohn's disease defined as a Crohn's Disease Activity Index (CDAI) score from
             220 and 450, inclusive, at Screening.

          -  Active inflammatory disease as defined by Crohn's Disease Endoscopic Index of Severity
             (CDEIS) ≥ 8 (as determined by a Central Blinded Reader) at Screening.

          -  Tumor Necrosis Factor (TNF)-naïve or previously exposed to a single anti-TNF agent
             (such as infliximab, adalimumab or certolizumab pegol) with treatment discontinued at
             least 8 weeks prior to Screening due to inadequate response, loss of response or
             intolerance as judged by the Investigator.

          -  Must have adequate renal and hepatic function as adjudged by the Investigator.

          -  In good health (other than Crohn's disease) as evidenced by medical history and
             physical examination.

        Exclusion criteria

        Subjects will be entered into this study only if they meet none of the following criteria:

          -  Subjects who are pregnant, breastfeeding, or of child-bearing potential and not using
             a medically accepted form of contraception.

          -  Presence of fistulas, ileostomies, colostomies or rectal pouches or history of
             proctocolectomy or total colectomy. Subject has an ostomy or ileoanal pouch (subjects
             with a previous ileorectal anastomosis are not excluded).

          -  Subject has short bowel syndrome as determined by the Investigator.

          -  History of evidence of colonic mucosal dysplasia.

          -  Subject currently has a significant mechanical obstruction (stenosis).

          -  Subject has a current diagnosis of ulcerative or indeterminate colitis.

          -  Immunization with a live vaccine within 4 weeks of Screening, with the exception of
             influenza vaccine and no planned immunizations within the period of the study.

          -  Active or latent tuberculosis (TB) or tuberculosis infection; TB assessment and
             prophylaxis will be performed as per local biologicals regulations and guidelines.

          -  Subjects with a history of or ongoing chronic or recurrent infectious disease within
             the 12 months prior to Screening.

          -  Positive stool culture for Clostridium within the last 6 months prior to Screening.

          -  Use of prohibited medications/procedures, including;

               -  Concomitant corticosteroids doses exceeding 20 mg/day of prednisone (equivalent)

               -  Concomitant use of budesonide

               -  Concomitant use of anti-TNF therapy

               -  Subjects who received previous treatment with more than one anti-TNF agent

               -  Concomitant use of cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil

               -  Prior or concomitant use of anti-α4 integrin or other non-TNF blocking biological

               -  Use of tube or enteral feeding, elemental diet, or parenteral alimentation
                  started within 2 weeks prior to Screening

               -  Leukocytapheresis or granulocytapheresis within 2 weeks prior to Screening

          -  Use of any prescription medications/products (with the exception of prescription
             medications for contraception and/or medications deemed acceptable by the Investigator
             and Sponsor).

          -  Use of any over the counter (OTC), non-prescription preparations (including vitamins,
             minerals, phytotherapeutic/herbal/plant-derived preparations) within 7 days prior to
             the Check-in visit (Day 0), unless deemed acceptable by the Investigator and Sponsor.

          -  Current or recent history (within 6 months of screening) of drug or substance abuse,
             including alcohol ≥ 14 units per week or who have a significant history of alcoholism
             or drug/chemical abuse within 6 months prior to the Screening visit (one unit of
             alcohol equals 0.5 pint [285 mL] of beer or lager, one glass [125 mL] of wine, or 1
             shot [25 mL] of spirits).

          -  Subjects with known clinically significant cardiac disease (e.g., myocardial
             infarction or stroke within 6 months prior to Screening, unstable angina,
             claudication, etc.), or evidence of a clinically significant electrocardiogram (ECG)
             abnormality at Screening.

          -  A history of significant neurologic, hepatic, renal, endocrine, cardiovascular,
             gastrointestinal, pulmonary or metabolic disease within 30 days of the Screening
             visit, as judged by the Investigator.

          -  Have a family history (more than one first degree relative) of multiple thrombotic
             events or a personal history of any venous or arterial thrombotic event including deep
             vein thrombosis, stroke, myocardial infarction, pulmonary embolus, and peripheral
             arterial thromboembolic events.

          -  Subject has had a positive hepatitis panel (including hepatitis B surface antigen
             [HBsAg], hepatitis B core antibody, and hepatitis C virus antibody [anti-HCV]) or a
             positive HIV antibody screen at time of Screening.

          -  Evidence of hepatic dysfunction, viral hepatitis, or current or chronic history of
             liver disease including non-alcoholic steatohepatitis (NASH) or abnormal hepatic
             markers (AST, ALT, ALP, or total bilirubin &gt; 1.5 x upper limit of normal) at the time
             of the Screening visit.

          -  Abnormal renal function (BUN or creatinine &gt;1.25 x upper limit of normal) at the time
             of the Screening visit.

          -  White Blood Cells &lt;4 x 103/mm3; platelets &lt;150 x 103/mm, hemoglobin &lt; 6.2 mmol/L at
             the time of the Screening visit.

          -  Subjects with evidence of other serious, significant, acute or chronic medical or
             psychiatric illness that, in the judgment of the Investigator, could compromise
             subject safety, limit the subject's ability to complete the study, and/or compromise
             the objectives of the study.

          -  History of malignancy, with the exception of resected basal cell carcinoma, squamous
             cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ.

          -  Active acute infection requiring systemic treatment for more than 2 weeks.

          -  Planned surgery during the study period or have undergone major surgery within the 3
             months prior to the Screening visit.

          -  Subjects who have received any investigational drug within 60 days or use of other
             experimental anti-CD therapies within the last 30 days prior to Screening visit.

          -  Known sensitivity to any component of the study drug or previous sensitivity reaction
             or other clinically significant reaction to intravenous medications or biologic
             therapy.

          -  Subjects who have previously received FFP104 or have been previously enrolled in this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gert van Assche, Prof. Dr.</last_name>
      <phone>+32 16 34 42 25</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janneke van der Woude, Prof. Dr.</last_name>
      <phone>+31 107040126</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

